Deepening Guangdong-NSW Collaboration: Deputy Secretary of NSW Ministry of Health Visits Guangdong Medical Valley for Exchange

From December 2 to 4, 2025, the Guangdong-New South Wales Joint Economic Conference was held in Guangzhou. On December 2, under the coordination of the New South Wales Trade and Investment Office,Dr. Jean-Frédéric Levesque, Deputy Secretary of the New South Wales Ministry of Health, Australia, along with representatives from seven biopharmaceutical companies in New South WalesVisit and exchange at MEDV·Nansha Life Science Park (Phase I).Xie Jiasheng, Executive President of MEDV, and Huang Heting, Director of the International Medical Industry Innovation CenterAndHead of External Cooperation Department, Wang WanweiWarmly welcome and receive the guests.

The first stop of the inspection tour was a visit to the park enterprises by the delegation.MingMed。Dr. Hui Ouyang, Chief Scientist of the CompanyThe team provided the visitors with a detailed introduction to the company’s development. MingMed Biotechnology Co., Ltd., located in Guangzhou, is a Chinese enterprise focused on the independent research and development of innovative drugs with global competitiveness. The company has a research and development team led by several world-renowned scientists and experts. Relying on its strong R&D capabilities and highly efficient operational abilities, MingMed has independently developed a diversified and synergistic product pipeline, including recombinant protein botulinum toxin, ophthalmic drugs, tumor immunotherapy drugs, and pet immunotherapy drugs. This pipeline features multiple potential first-in-class innovative drugs, and all major products are nearing commercialization.

Subsequently, the delegation visited the park enterprises.Tiankeya。Dr. Su Zhenbo, CEO and Co-founderThe team introduced the company's innovative progress to the visitors. Tiankeya is a biopharmaceutical company in China at the clinical stage, focusing on the innovation, development, and clinical translation of cellular immunotherapy for solid tumor treatment. Relying on several self-developed cell engineering platform technologies, the company is currently advancing eight R&D pipelines, exploring the application prospects of immune cell therapy in various cancer fields.

That afternoon, the delegation visited the MEDV exhibition hall and held a symposium. FromThe First People's Hospital of Guangzhou - Cell and Gene Therapy (CGT) Center, MingMed, Raythera Bio, EHang Bio, UminiBio, ForSight VISION, RunSheng Cell, YiFei Bio, HisCalMore than ten institutional and corporate representatives participated in the exchange.Xie Jiasheng, Executive President of MEDVIn the speech, he reviewed the long-term cooperation with New South Wales: since 2017, joining hands with the New South Wales Trade and Investment Office to establish "China-Australia Medical Industry Innovation Center"Since then, MEDV has cooperated with New State 30 times, including six special对接events and three overseas investigations, assisting 86 New State enterprises in对接ing nearly 200 Chinese institutions. Relevant work has been awarded by the Australian Trade Commission."Outstanding Contribution Award for Australia-China Medical Health Cooperation”。

Dr Jean-Frédéric LevesqueHighly praised the achievements of MEDV in international cooperation and the technological innovation of participating enterprises, and stated that New South Wales possessesFastest Approval Speed, R&D Tax Incentives, Diverse Population, and the Largest Biobank in the Southern HemisphereAnd other advantages have made it an emerging destination for Chinese pharmaceutical companies and Biotech to expand overseas. He welcomed more outstanding companies in the Greater Bay Area to learn about New Jersey, visit New Jersey, and establish cooperation with New Jersey.

During the discussion, both parties engaged in a lively conversation on topics such as scientific research collaboration and overseas clinical trials, reaching several preliminary cooperation intentions.

During the Guangdong-Xinjiang Joint Economic Conference held from December 3rd to 4th, MEDV organized multiple enterprises to attend the biopharmaceutical sub-forum and the "Friends of Xinzhou" exchange event, continuously building a pragmatic cooperation platform for enterprises from both regions.

Taking the 30th Guangdong-Singapore Joint Economic Conference as a new starting point, MEDV will continue to optimize the service mechanism of the "China-Australia Medical Industry Innovation Center," actively promote the settlement of Singaporean enterprises in the Greater Bay Area, assist Chinese biopharmaceutical enterprises in going global, and continuously empower the innovative win-win development of the China-Australia medical industry.